|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Coronary Vasospasm | |||||
| 2 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Coronary Disease | |||||
| Heart Diseases | |||||
| Myocardial Ischemia | |||||
| Vascular Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| single dose Sildenafil | |||||
| Single dose placebo | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Sildenafil | |||||
| 5 | More general drug interventions related to this trial | ||||
| Cardiovascular Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Phosphodiesterase Inhibitors | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) | |||||